保荐人 · 2026-02-19

Analysis of Indicators of Impairment for Long-Term Equity Investments in Sponsor Due Diligence

The SFC’s 2024 annual enforcement report recorded 194 active investigations into sponsor and intermediary misconduct, with a notable increase in cases involving the valuation of unlisted long-term equity investments. This trend coincides with the HKEX’s December 2024 consultation conclusion on Listing Rules amendments for Chapter 18C (Specialist Technology Companies) and Chapter 18B (SPACs), which expanded the scope of mandatory due diligence on investee company valuations. For sponsors licensed under the SFC’s Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission (the SFC Code), the identification and assessment of impairment indicators for long-term equity investments held by listing applicants or listed issuers has become a recurrent compliance flashpoint. The SFC’s December 2023 circular on sponsor due diligence in relation to financial performance and asset impairment explicitly reminded sponsors that a failure to identify objective evidence of impairment—such as a significant decline in market capitalisation, adverse changes in the technological, market, economic, or legal environment, or a history of or continuing losses—constitutes a breach of paragraph 17 of the SFC Code, which requires sponsors to exercise due skill, care, and diligence. This article examines the specific indicators of impairment that sponsors must evaluate during the due diligence process, the regulatory expectations for documentation, and the practical implications of recent enforcement actions.

The Regulatory Framework for Impairment Assessment in Sponsor Due Diligence

Paragraph 17 of the SFC Code and the Sponsor’s Duty of Care

The SFC Code, under paragraph 17, imposes a non-delegable duty on sponsors to ensure that all information in a listing document is true, accurate, and complete, and not misleading. This duty extends to the sponsor’s assessment of whether a listing applicant’s long-term equity investments are impaired. The SFC’s 2023 circular on sponsor due diligence in relation to financial performance and asset impairment (the 2023 SFC Circular) explicitly states that sponsors must not rely solely on management’s assertions or on the absence of a qualified audit opinion. Instead, sponsors must independently evaluate the indicators of impairment set out in Hong Kong Accounting Standard 36 (HKAS 36) Impairment of Assets, which is the relevant financial reporting standard under the Hong Kong Financial Reporting Standards (HKFRS) framework.

HKAS 36 requires an entity to assess at each reporting date whether there is any indication that an asset may be impaired. For long-term equity investments accounted for under HKAS 28 Investments in Associates and Joint Ventures or HKFRS 9 Financial Instruments, the indicators include external sources of information (e.g., significant adverse changes in the technological, market, economic, or legal environment in which the investee operates) and internal sources (e.g., evidence of obsolescence or physical damage, or a history of or continuing losses). The SFC expects sponsors to document a systematic review of these indicators, not merely a check-box exercise.

The HKEX’s Position in Listing Decisions and Guidance

The HKEX’s Listing Decision LD117-2023 (December 2023) provides a clear example of the Exchange’s scrutiny of impairment assessments in the context of a Main Board listing applicant. In that decision, the HKEX rejected the listing application of a company whose long-term equity investment in a BVI-incorporated associate had been carried at cost for three consecutive years, despite the associate having reported net losses of HKD 45 million, HKD 62 million, and HKD 78 million over the same period. The HKEX concluded that the sponsor had failed to identify the impairment indicator arising from the associate’s continuing losses, and had not performed a recoverable amount test under HKAS 36. The decision cited the sponsor’s reliance on a management-prepared valuation report that used an unsubstantiated discount rate of 8.5% without benchmarking to comparable market data. The HKEX’s Listing Rules, specifically Rule 11.07, require that a listing document contain sufficient information to enable an investor to make an informed assessment of the issuer’s financial position, and the failure to disclose the impairment assessment was deemed a material omission.

Key Indicators of Impairment for Long-Term Equity Investments

External Indicators: Market, Economic, and Legal Environment Changes

The most frequently cited external indicator in SFC enforcement actions is a significant decline in the market capitalisation of the investee. Under HKAS 36.12(a), a decline in market value that is more than temporary is an indicator of impairment. In practice, sponsors must compare the investee’s market capitalisation (if listed) or its most recent funding round valuation (if unlisted) against the carrying amount of the investment. The SFC’s 2023 Circular cites a case where a sponsor failed to flag that the investee’s share price had fallen by 72% over 12 months, from HKD 4.50 to HKD 1.26, while the investment was carried at HKD 3.80 per share. The SFC held that the sponsor should have identified this as an impairment indicator and performed a recoverable amount test.

Other external indicators include adverse changes in the technological environment (e.g., a competitor’s launch of a superior product that renders the investee’s technology obsolete), changes in market or economic conditions (e.g., a sustained downturn in the investee’s industry, such as the 2022-2023 correction in the PRC property sector), and changes in the legal or regulatory environment (e.g., the PRC’s 2021 Opinions on Further Strengthening the Supervision of Capital Market Intermediaries, which tightened rules on VIE structures and cross-border data transfers). For sponsors conducting due diligence on PRC-based investees, the 2023 SFC Circular specifically references the need to assess the impact of the PRC’s Cybersecurity Law and Data Security Law on the investee’s ability to continue operations, as these laws may constitute an adverse legal environment change under HKAS 36.12(b).

Internal Indicators: Financial Performance and Operational Evidence

Internal indicators under HKAS 36.12(c)-(d) include evidence of obsolescence or physical damage, significant changes in the extent or manner in which the asset is used, and a history of or continuing losses. For long-term equity investments, the most common internal indicator is the investee’s failure to meet its business plan or budget. The SFC expects sponsors to obtain and review the investee’s management accounts, board minutes, and cash flow projections for at least the 12 months preceding the listing application date. In SFC enforcement case SFC v. [Sponsor Firm A] (2023), the Court of First Instance found that the sponsor had breached paragraph 17 by failing to review the investee’s internal management accounts, which showed that the investee had breached its debt covenants and was in negative net asset position of USD 12.3 million. The Court held that the sponsor’s reliance on the investee’s audited financial statements (which were 9 months old at the time of the listing application) was insufficient.

Another critical internal indicator is the investee’s inability to generate sufficient cash flows to service its debt or fund its operations. Under HKAS 36.14, if the investee’s net asset value is negative, or if its current liabilities exceed its current assets, this is a strong indicator of impairment. Sponsors must obtain the investee’s latest management accounts and compare the net asset value to the carrying amount of the investment. In LD117-2023, the HKEX noted that the investee’s net asset value had fallen from HKD 150 million to HKD 22 million over two years, yet the sponsor had not performed a recoverable amount test. The Exchange’s decision emphasised that the sponsor should have identified the negative trend as an impairment indicator, even if the net asset value remained positive.

Practical Application: Recoverable Amount Testing and Documentation

The Recoverable Amount Test Under HKAS 36

Once an indicator of impairment is identified, HKAS 36 requires the entity to estimate the recoverable amount of the asset. The recoverable amount is the higher of the asset’s fair value less costs of disposal (FVLCD) and its value in use (VIU). For long-term equity investments in unlisted entities, the FVLCD is typically determined using a market approach (e.g., reference to recent arm’s length transactions or earnings multiples of comparable listed companies) or an income approach (e.g., discounted cash flow analysis). The VIU is calculated using pre-tax cash flow projections and a pre-tax discount rate that reflects the time value of money and the risks specific to the asset.

The SFC’s 2023 Circular provides detailed guidance on the sponsor’s role in this process. The sponsor must not simply accept management’s valuation; it must challenge the key assumptions, including the discount rate, the growth rate, and the forecast period. The Circular cites a case where management used a discount rate of 10.2% based on the investee’s weighted average cost of capital (WACC), but the sponsor’s independent analysis showed that the appropriate rate should have been 14.8%, reflecting the investee’s higher country risk premium (PRC-specific risk of 3.5%) and a smaller market capitalisation premium of 1.1%. The SFC held that the sponsor’s failure to challenge the discount rate constituted a breach of paragraph 17.

Documentation Standards for Sponsor Compliance

The SFC expects sponsors to maintain a clear audit trail of their impairment assessment. This includes a written analysis of each indicator identified, the rationale for concluding whether the indicator is present, and, if so, the recoverable amount test performed. The documentation should be contemporaneous, meaning it must be prepared during the due diligence process, not after the fact. In SFC enforcement case SFC v. [Sponsor Firm B] (2024), the SFC fined the sponsor HKD 15 million for failing to document its assessment of impairment indicators for three long-term equity investments. The sponsor had relied on verbal discussions with management and had not prepared any written analysis. The SFC’s Statement of Disciplinary Action stated that the sponsor’s failure to maintain adequate records was a systemic deficiency that undermined the quality of its due diligence.

Sponsors should also document their review of the investee’s impairment assessment performed by the investee’s own auditors. Under HKAS 28.35, an entity must apply HKAS 36 to its investments in associates and joint ventures. The sponsor should obtain the investee’s impairment testing working papers and reconcile the assumptions used to the sponsor’s independent analysis. If the investee has not performed an impairment test, the sponsor must note this as a red flag and consider whether the listing applicant’s financial statements are materially misstated.

Recent Enforcement Trends and Their Implications for Sponsors

The SFC’s Focus on Unlisted Investments and VIE Structures

The SFC’s enforcement priorities for 2025-2026, as outlined in its Annual Enforcement Report 2024, include a specific focus on sponsor due diligence relating to unlisted long-term equity investments, particularly those held through VIE structures in the PRC. The SFC noted that VIE structures often involve complex contractual arrangements that obscure the economic substance of the investment, making impairment assessment more challenging. In one case cited in the report, a sponsor failed to identify that the investee’s VIE agreements were not legally enforceable under PRC law, which constituted an adverse legal environment change under HKAS 36.12(b). The SFC fined the sponsor HKD 8 million and suspended its licence for 12 months.

Sponsors should also be aware of the HKEX’s revised Listing Rules for Specialist Technology Companies (Chapter 18C, effective 31 March 2024), which require listing applicants to provide detailed disclosure on the valuation of their long-term equity investments. The HKEX’s Guidance Letter GL117-23 (December 2023) states that the Exchange may request the sponsor’s impairment assessment working papers as part of its vetting process. This means that sponsors must be prepared to produce their documentation to the HKEX on demand, and any gaps in the analysis will be subject to scrutiny.

The Impact of the PRC’s New Company Law on Impairment Indicators

The PRC’s revised Company Law, effective 1 July 2024, introduces new provisions on the duties of directors and supervisors, including a statutory duty of care and loyalty. For sponsors assessing impairment indicators for PRC-based investees, this law has direct implications. Under the new law, if an investee’s directors fail to declare the company’s insolvency or to take steps to prevent further losses, this may constitute evidence of a breakdown in corporate governance, which is an internal indicator of impairment under HKAS 36.12(d). Sponsors should review the investee’s board minutes and compliance with the new law to assess whether there is evidence of director misconduct that could impair the value of the investment.

In addition, the PRC’s Supreme People’s Court’s Interpretation on the Application of the Company Law (2024) clarifies the circumstances under which a shareholder can claim for diminution in the value of its investment. This interpretation may affect the recoverable amount of a long-term equity investment, as it provides a legal basis for a shareholder to seek damages if the investee’s value has been impaired by director misconduct. Sponsors should consider whether the investee’s legal exposure under this interpretation constitutes an adverse legal environment change.

Actionable Takeaways for Sponsors

• Sponsors must independently verify all indicators of impairment under HKAS 36.12 for each long-term equity investment, including a review of external market data and internal management accounts, and document the analysis contemporaneously in the due diligence file.
• The recoverable amount test must be performed using independent valuation assumptions benchmarked to market data, with the discount rate, growth rate, and forecast period subject to rigorous challenge, not merely accepted from management.
• For investments in PRC-based entities, particularly those using VIE structures, sponsors must assess the legal enforceability of the contractual arrangements under the PRC’s new Company Law and Data Security Law, and document the impact on the impairment assessment.
• The sponsor’s impairment assessment working papers must be prepared in a format that can be produced to the HKEX on demand, as the Exchange may request these documents under Listing Rule 11.07 and Guidance Letter GL117-23.
• Any failure to identify a material impairment indicator, or to perform a recoverable amount test, will be treated by the SFC as a breach of paragraph 17 of the SFC Code, with penalties ranging from fines of up to HKD 15 million to licence suspension.